Our next test is based on placebo laws.
All the p values displayed are based on placebo runs that are described in Sect.
The placebo model was first developed based on the placebo data alone.
The objective of this analysis was to better understand disease progression among geographic regions in the setting of multinational AD clinical trials, based on analysis of placebo data from the IDENTITY and EXPEDITION study programs.
A decision model will be developed, from the perspective of the NHS, to estimate the costs and health outcomes in terms of quality of life and quality-adjusted life-years associated with gabapentin and placebo based on the data from this pilot study and the literature.
This study represents an important advance relative to previously published works, which were based on modelling data from placebo-controlled clinical trials [ 39].
Based on available data, mainly from placebo-controlled trials, the current formulations appear to be comparable in terms of efficacy and safety.
Non-inferiority of the Q3W regimen was determined if the upper limit of the 95% CI for this difference was ≤12.5% (based on transfusion data from two placebo-controlled darbepoetin alfa trials) [ 8, 10].
Our analyses are based on data from the placebo arm of the adjuvant Tykerb evaluation after chemotherapy (TEACH) trial (ClinicalTrials.gov number NCT00374322), the design and main outcomes of which have been previously published [ 3].
A multiplicity correction using a Bonferroni adjustment with was applied, despite the fact that in the final efficacy analysis only the two selected indacaterol doses should have been compared individually against placebo based on the pooled data of both stages with prefixed sample sizes.
